Abstract PS2-10-04: Tumor-infiltrating lymphocytes - a promising predictive and prognostic biomarker for optimizing neoadjuvant treatment response: a single-institution retrospective analysis
Retrospective analysis evaluates tumor-infiltrating lymphocytes' impact on neoadjuvant treatment response in breast cancer, indicating their predictive and prognostic value.
Key Points
The research aims to evaluate the role of tumor-infiltrating lymphocytes (TILs) in predicting response to neoadjuvant therapy across breast cancer subtypes.
Retrospective analysis of 181 early-stage breast cancer patients treated with neoadjuvant therapy.
Assessment of residual cancer burden (RCB) scores to evaluate treatment response.
TIL levels were categorized and analyzed based on breast cancer subtypes, focusing on HER2-positive and triple-negative cases.
Increased TIL levels were associated with improved response rates to neoadjuvant therapy, especially in HER2-positive and triple-negative subtypes.
HER2-positive patients receiving anti-HER2 therapy showed a higher rate of RCB 0-I compared to those who did not (66.7% vs. 40%).
In triple-negative cases, incorporating immune checkpoint inhibitors improved outcomes for patients with low TILs, contrasting with those who had not received ICI.